...

MID-35

CAS
2757831-08-4
Molecular wt
2350.9
Compound class
Synthetic D-amino acid peptide

Third-party tested. Every batch.

Independent labs test each lot before it ships. The certificates are published here, filed by batch number, for anyone to read.

Browse all COAs

MID-35

MID-35 10mg Lyophilized Peptide in 3mL Vial

MID-35 is sold strictly for in vitro research and educational purposes. It is not intended for human or animal consumption. MID-35 is not a dietary supplement, food, or drug. By purchasing this product, the buyer agrees to use it only in lawful research applications and assumes full responsibility for compliance with all applicable local, state, and federal regulations. Kimera Chems makes no therapeutic or diagnostic claims regarding this compound.

Description

MID-35 (Myostatin Inhibitory D-Peptide)

MID-35 is a synthetic, 16-amino-acid retro-inverso D-peptide designed as a selective inhibitor of myostatin (Growth Differentiation Factor 8, GDF-8). By utilizing a retro-inverso configuration—reversing the amino acid sequence and employing D-form residues—MID-35 maintains the precise spatial orientation required for myostatin binding while achieving significant resistance to proteolytic degradation. This structural design makes it a specialized tool for studying myostatin-mediated signaling and muscle growth regulation in controlled in vitro and in vivo laboratory models.

Technical Specifications

Property Specification
Product Name MID-35
Peptide Class 16-amino-acid retro-inverso D-peptide
Molecular Weight ~2350 Da
Mechanism Myostatin/ActRIIB signaling inhibition
Physical Appearance White to off-white lyophilized powder
Assay Purity Refer to the batch-specific Certificate of Analysis (COA) supplied for the lot received

Mechanism of Action & Research Context

Myostatin acts as a negative regulator of skeletal muscle growth by signaling through the activin receptor type IIB (ActRIIB). This process recruits type I receptors (ALK4/ALK5) and triggers downstream Smad2/3 phosphorylation, which inhibits myogenic gene transcription.

  • Selective Inhibition: MID-35 binds directly to the myostatin/activin type I receptor interface, effectively blocking Smad2/3 signaling activation.

  • Selectivity Profile: Unlike decoy receptor strategies or broad-spectrum inhibitors (e.g., follistatin), MID-35 exhibits high selectivity for myostatin, minimizing neutralization of other TGF-β superfamily ligands like activin A or BMP9/10.

  • Enzymatic Stability: The D-amino acid configuration provides superior resistance to standard proteolytic enzymes compared to conventional L-peptide inhibitors, enhancing stability in research applications.

Research Applications

MID-35 serves as a high-potency probe for investigating muscle atrophy, sarcopenia, and myostatin-mediated signaling pathways.

Primary fields of laboratory investigation include:

  • Myogenic Signaling Research: Evaluating the modulation of muscle growth and atrophy gene expression (e.g., MyoD, Atrogin-1, MuRF-1).

  • Cachexia Models: Studying the alleviation of skeletal muscle atrophy in disease-state models (e.g., cancer cachexia) and synergy with other metabolic modulators.

  • Non-Invasive Delivery Systems: Investigating transdermal delivery technologies, such as iontophoresis, for peptide transport into skeletal muscle.

  • Structure-Activity Relationship (SAR): Comparative analysis of retro-inverso vs. L-peptide configurations in myostatin binding potency.

Storage & Handling Guidelines

Store at controlled room temperature, sealed and protected from light.

Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.

Related Research Compounds

Further reading: MID-35 research overview

Key Preclinical Literature

  • Takayama K, et al. (2022) Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice. ACS Med. Chem. Lett. 13(3):492–498.

  • Hanada K, et al. (2022) Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model. Cancer Sci. 113(11):3766–3779.

  • Michiue K, et al. (2023) Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis. Pharmaceuticals. 16(3):397.

Research Use Disclaimer

Research Use Only Disclaimer: This product is developed and distributed strictly as a Research Use Only (RUO) laboratory reference chemical intended exclusively for non-clinical analytical and scientific investigation. It is not an FDA-approved drug, medical treatment, dietary supplement, or food ingredient, and is strictly prohibited for human or animal consumption. Kimera Chems supplies this research material solely to qualified institutions and professional investigators for authorized laboratory research purposes.

Compound Class Synthetic D-amino acid peptide
CAS Number 2757831-08-4
IUPAC Name D-Leucyl-D-arginyl-2-cyclohexyl-D-glycyl-D-lysyl-D-arginyl-D-tryptophyl-D-isoleucyl-D-arginyl-2-cyclohexyl-D-glycyl-D-lysyl-D-isoleucyl-D-tryptophyl-D-arginyl-D-isoleucyl-D-tyrosyl-D-tryptophanamide.
Molecular Formula C118H184N34O17
Molecular Weight 2350.9

Certificates of Analysis

Kimerachems
By starting a chat with our artificial intelligence-powered assistant, you agree to the automated processing of your personal data.
Kimera Chems assistant
...